Conference Day One

Wednesday 13th September 2023

8:00 am Welcome Coffee & Registration

9:15 am Chair’s Opening Remarks

9:20 am Overcoming Heterogeneity of LNP Structure & Morphology to Establish a Greater Understanding of Encapsulation Efficiency

9:30 am Examining the Morphology of the LNP to Advance Understanding of the Functional Impact

  • Sixuan Li Postdoctoral research assistant, Pfizer


• In-depth Characterization of LNP to Enhance Product Understanding

• Ensuring detailed understanding of the molecular structure of LNP surface

• Higher resolution analysis of size distribution of LNP

• Seeing is believing with image analysis for LNP size and morphology

10:00 am Techniques to Overcome Heterogeneity Challenges for a Deeper Understanding of LNP Properties


  • Recognizing major sources of heterogeneity and consistency throughout the LNP formulation process
  • Impact of heterogeneity of LNP efficacy and potency and the pivotal role of QC and QA
  • Developing tools to standardize characterization and analytical methods with increased variability across LNPs constituents

10:30 am Linking LNP Physicochemical and Biological Properties to Better Understand their Safety


  • Structure-activity relationships between LNP components and biological responses (inflammation, toxicity, biodistribution, clearance)
  • PEG and PEG alternatives
  • In vitro and in vivo models for safety studies of LNPs
  • In silico models, computer-based and AI-algorithms to predict LNP safety profiles

11:00 am Morning Refreshments, Speed Networking and Tech Slam

11:30 am Aligning the Industry approach of Quality Control Metrics to Translate Data Efficiently to Maximize Integrity & Purity of the LNP Complex

12:00 pm Roundtable discussion – Tackling Impurity Thresholds to Review the Required Target with an Appreciation of Degradation Impact

  • Chris Broomell Head of Analytical Development, Omega Therapeutics, Inc.


  • Reviewing what ‘good’ looks like when striving for purity 
  • Correlating impurity metrics with risk of degradation 
  • Discussing realistic purity metrics to maximise control as well time efficiency 

12:45 pm Assessment of LNP Qualities & RNA loading by Nano-flow Cytometry


  • Quantify particle concentrations and size distribution >40nm label-free
  • Simultaneously identify encapsulated or surface-presented material in loaded subpopulations using fluorescence
  • Multi-parameter measurement of a range of nanoparticles with flexible labelling of targetable material 

1:00 pm Analysing the Lipid Composition Following LNP Formulation to Increase Nanoparticle Purification

  • David Foley Director - Analytical Research & Development, Merck


  • Benchmarking success when characterizing the lipid composition to maximize purity following LNP formulation
  • Understanding the purity outcomes with multiple lipids and conjugates as well as a payload through accurate characterization 
  • Distinguishing lipid compartments and ratios with an appreciation of impurity production 

1:30 pm Lunch & Networking

2:00 pm Optimizing Payload Characterization to Better Predict LNP Complex Outcome

2:30 pm Evaluating the Technology Available to Execute Thorough Characterization of LNPs


  • Exploring the future of LNP characterization and analytical development with emerging technologies holding promise
  • Debating the strengths and weaknesses of the current analytical tools available to market
  • Contrasting the technologies used in academic research in comparison to industry 

3:00 pm Probing Structure and Conformation of mRNA-Lipid Nanoparticles


  • Reviewing the characterization tools in use to profile the mRNA drug substance 
  • Understanding the conformational changes of the LNP that occur following the encapsulation of the mRNA 
  • Debating how the function of the LNP complex can be relayed back to the initial characterization of the LNP and mRNA

3:30 pm Chair’s Closing Remarks

3:45 pm End of Day 1